Clinical Trials Logo

Metastatic NSCLC clinical trials

View clinical trials related to Metastatic NSCLC.

Filter by:

NCT ID: NCT03589339 Recruiting - Immunotherapy Clinical Trials

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Start date: January 16, 2019
Phase: Phase 1
Study type: Interventional

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

NCT ID: NCT03417882 Terminated - Metastatic NSCLC Clinical Trials

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Start date: January 3, 2019
Phase: Phase 2
Study type: Interventional

This is a non-randomized, Phase 2, 2-stage, open-label, multi-center study of GRN-1201/sargramostim + pembrolizumab in subjects with PD-L1+ metastatic NSCLC. All subjects will have newly diagnosed metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Subjects with EGFR or ALK genomic tumor aberrations with progression on FDA-approved therapy for these aberrations are eligible

NCT ID: NCT01438307 Completed - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Lung cancer is the leading cause of cancer death worldwide and in the United States. The majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases are advanced at the time of diagnosis. Chemotherapy has improved overall survival but remains limited at < 12 months median overall survival. New approaches are needed for second line chemotherapy treatment. Cabazitaxel-XRP6258 has shown increased overall survival in metastatic prostate cancer and it is hopeful it can do the same in advanced NSCLC.